powerpoint 프레젠테이션 · 2019-10-29 · 17 diabetes/obesity rare diseases cancer autoimmune...

2

3

4

5

AUG

OCT

SEP

(5.7%)

6

7

39.95.02.2

(3.4%)

8

9

10

11

12

13

14

15

16

17

Diabetes/Obesity

Rare diseases

Cancer

Autoimmune diseases

Others

B Beijing Hanmi

Pre-Clinical Phase 2 Phase 3Phase 1

LAPSGCG ComboHM14320Obesity/Diabetes/NASH

GBM Stem Cell TherapyHM21001Glioblastoma

AJOU Univ

LAPSTriple AgonistHM15211NASH

LAPSGCG AnalogHM15136Obesity/Congenital Hyperinsulinism

PD-1/CD47BH29XXTargeted Immuno-oncology

B

LAPSASBHM15450Mucopolysaccharidosis

LAPSGLP/GCGHM12525AObesity/Diabetes

LAPSIns/LAPSInsulin AnalogHM12460A/HM12470Diabetes

Pan-RAF InhibitorBelvarafenibSolid tumors

GENENTECH

PD-1/PD-L1BH2996HTargeted Immuno-oncology

B

EfpeglenatideLAPSExd4 AnalogObesity/Diabetes

SANOFI

EfpegsomatropinLAPShGHGH deficiency

Luminate®

Integrin inhibitor

DMEALLEGRO

BTK InhibitorHM71224Autoimmune disease

Pan-HER InhibitorPoziotinibSolid tumor

SPECTRUM

Rolontis™EflapegrastimNeutropenia

SPECTRUM

Oraxol™Paclitaxel+HM30181ASolid tumor

ATHENEX

PD-1/HER2BH2950Targeted Immuno-oncology

B

INNOVENT

FLT3 InhibitorHM43239

AML

TNF-α/IL-17BH1657Targeted Autoimmune diseases

B LAPSGLP-2 AnalogHM15912Short Bowel Syndrome

LAPSInsulin148HM12480Diabetes

LAPSInsulin ComboHM14220Diabetes

Luminate®

Integrin inhibitorRetinitis Pigmentosa

Oratecan™Irinotecan+HM30181ASolid tumor

Oradoxel™Docetaxel+HM30181ASolid tumor

ATHENEX

ATHENEX

A2AR antagonist

Solid tumor

LSD1 Inhibitor

SCLC, AML

SANOFI

18